@article{b48b1fb00d524de392d1831483367fb5,
title = "DUB be good to me",
abstract = "Induced proximity is reshaping drug discovery. A new study debuts deubiquitinase-targeting chimeras (DUBTACs), small bifunctional molecules that co-opt a deubiquitinase to stabilize a target protein.",
keywords = "Chemical tools, Post-translational modifications, Small molecules",
author = "Xingui Liu and Alessio Ciulli",
note = "Funding Information: A.C. is a scientific founder, shareholder and advisor of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Nurix Therapeutics and Ono Pharmaceutical.",
year = "2022",
month = apr,
doi = "10.1038/s41589-022-00978-9",
language = "English",
volume = "18",
pages = "358--359",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "Nature Publishing Group",
}